AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
This article was originally published in The Pink Sheet Daily
Executive Summary
Seroquel is the first drug approved for both depressive and manic episodes associated with bipolar disorder, the firm says.
You may also be interested in...
AstraZeneca Tries For Seroquel XR Approvals In Europe
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.
AstraZeneca Tries For Seroquel XR Approvals In Europe
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.
AstraZeneca’s Seroquel XR Gets FDA Nod For Once-Daily Treatment Of Schizophrenia
AstraZeneca plans to have the extended-release tablets on the market by late July, firm tells “The Pink Sheet” DAILY.